

Meta-analysis confirms effectiveness of BioGaia ProDentis in periodontitis

In a newly published systematic review of probiotics as adjunct to standard treatment of periodontitis the proof for *Lactobacillus reuteri* Prodentis was confirmed, as it was shown to be the only probiotic effective in patients with chronic periodontitis.

According to the authors the results are similar to those of other adjuncts to treatment of periodontitis, such as systemic antibiotics.

The meta-analysis is the first for probiotics in periodontal treatment. Only four studies, all using *Lactobacillus reuteri* Prodentis, were eligible for inclusion in the systematic review. As no other probiotic product qualified the analysis concludes that *Lactobacillus reuteri* Prodentis is the only probiotic that gives significant additional pocket reductions in moderate and deep dental pockets when used in combination with standard treatment of chronic periodontitis. In the trials *Lactobacillus reuteri* Prodentis consistently showed a statistically significant improvement versus standard treatment only.

”The meta-analysis confirms BioGaia ProDentis' unique position as the only clinically proven probiotic for patients with chronic periodontitis. Today dental professionals around the world can be reassured that they are suggesting an effective treatment when recommending BioGaia ProDentis as an adjuvant to standard treatment to their patients”, says Axel Sjöblad, Managing Director, BioGaia. “It is also encouraging that the authors suggest that *L. reuteri* may be used to reduce the use of systemic antibiotics and by that, potentially, lowering the risk for antibiotic resistance.”

The systematic review and meta-analysis was published online by researchers Olivier Huck and colleagues at Department of Periodontology, Dental Faculty, University of Strasbourg, France, in [Journal of Periodontology](#) 11 March 2016.

For additional information please contact

Axel Sjöblad, Managing Director, BioGaia, phone: +46 8 555 293 00

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com